GOSSAMER BIO, INC. Contract Liability (Deferred Revenue)
GOSSAMER BIO, INC. (GOSS) had Contract Liability (Deferred Revenue) of $7.07 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-13
- 2026-06-30: Contract with Customer, Liability, Current $7.07M.
- 2026-03-31: Contract with Customer, Liability, Current $8.74M.
- 2025-12-31: Contract with Customer, Liability, Current $19.99M.
- 2025-09-30: Contract with Customer, Liability, Current $23.97M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $7.07M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $8.74M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $19.99M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $23.97M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $23.47M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $17.85M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $17.05M 10-K · filed 2026-03-17 |
| 2024-09-30 | $20.33M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $17.01M 10-Q · filed 2024-08-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |